What Rhythm Pharmaceuticals Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 20 | 52 |
| Total trades | 26 | 101 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 212,437 | 530,408 |
| Disposed | 258,450 | 437,892 |
| Net activity | −46,013 | +92,516 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Meeker David P | President and CEO | Sep 14 | Disclosed 10b5-1 sale · S | −2,300 | $105.19 | −$242K | 239,258 |
| Meeker David P | President and CEO | Sep 14 | Disclosed 10b5-1 sale · S | −1,817 | $104.55 | −$190K | 241,558 |
| Meeker David P | President and CEO | Sep 14 | Disclosed 10b5-1 sale · S | −8,698 | $103.43 | −$900K | 243,375 |
| Meeker David P | President and CEO | Sep 14 | Disclosed 10b5-1 sale · S | −30,746 | $102.35 | −$3.15M | 252,073 |
| Meeker David P | President and CEO | Sep 14 | Disclosed 10b5-1 sale · S | −6,439 | $101.75 | −$655K | 282,819 |
| Meeker David P | President and CEO | Sep 14 | Exercise / conversion · M | +50,000 | $6.05 | +$303K | 289,258 |
| Smith Hunter C | Chief Financial Officer | Aug 31 | Disclosed 10b5-1 sale · S | −28,188 | $106.20 | −$2.99M | 114,024 |
| Smith Hunter C | Chief Financial Officer | Aug 31 | Disclosed 10b5-1 sale · S | −11,514 | $105.37 | −$1.21M | 142,212 |
| Smith Hunter C | Chief Financial Officer | Aug 31 | Disclosed 10b5-1 sale · S | −23,072 | $104.59 | −$2.41M | 153,726 |
| Smith Hunter C | Chief Financial Officer | Aug 31 | Exercise / conversion · M | +57,187 | $25.79 | +$1.47M | 176,798 |
| Chien Jennifer | EVP, Head of North America | Aug 13 | Open-market sale · S | −75,834 | $117.38 | −$8.9M | 0 |
| Chien Jennifer | EVP, Head of North America | Aug 13 | Exercise / conversion · M | +21,601 | $6.80 | +$147K | 75,834 |
| Chien Jennifer | EVP, Head of North America | Aug 13 | Exercise / conversion · M | +35,000 | $24.29 | +$850K | 54,233 |
| Garfield Alastair | Chief Scientific Officer | Aug 13 | Open-market sale · S | −800 | $119.17 | −$95.3K | 2,295 |
| Garfield Alastair | Chief Scientific Officer | Aug 13 | Open-market sale · S | −3,400 | $118.28 | −$402K | 3,095 |
| Garfield Alastair | Chief Scientific Officer | Aug 13 | Open-market sale · S | −1,556 | $117.08 | −$182K | 6,495 |
| Garfield Alastair | Chief Scientific Officer | Aug 13 | Open-market sale · S | −2,007 | $116.11 | −$233K | 8,051 |
| Shulman Joseph | Chief Technical Officer | Aug 13 | Open-market sale · S | −5,079 | $119.75 | −$608K | 15,915 |
| Shulman Joseph | Chief Technical Officer | Aug 13 | Exercise / conversion · M | +2,024 | $6.80 | +$13.8K | 20,994 |
| Mazabraud Yann | EVP, Head of International | Aug 12 | Disclosed 10b5-1 sale · S | −17,319 | $117.47 | −$2.03M | 55,655 |
Loading...